AIM: To investigate the mechanism of action of intra-arterial histamine in the human forearm vasculature. METHODS: Three studies were conducted to assess changes in forearm blood flow (FBF) using venous occlusion plethysmography in response to intra-brachial histamine. First, the dose-response was investigated by assessing FBF throughout a dose-escalating histamine infusion. Next, histamine was infused at a constant dose to assess acute tolerance. Finally, a four way, double-blind, randomized, placebo-controlled crossover study was conducted to assess FBF response to histamine in the presence of H1 - and H2 -receptor antagonists. Flare and itch were assessed in all studies. RESULTS:Histamine caused a dose-dependent increase in FBF, greatest with the highest dose (30 nmol min(-1) ) infused [mean (SEM) infused arm vs. control: 26.8 (5.3) vs. 2.6 ml min(-1) 100 ml(-1) ; P < 0.0001]. Dose-dependent flare and itch were demonstrated. Acute tolerance was not observed, with an increased FBF persisting throughout the infusion period. H2 -receptor antagonism significantly reduced FBF (mean (95% CI) difference from placebo at 30 nmol min(-1) histamine: -11.9 ml min(-1) 100 ml(-1) (-4.0, -19.8), P < 0.0001) and flare (mean (95% CI) difference from placebo: -403.7 cm(2) (-231.4, 576.0), P < 0.0001). No reduction in FBF or flare was observed in response to the H1 -receptor antagonist. Itch was unaffected by the treatments. Histamine did not stimulate vascular release of tissue plasminogen activator or von Willebrand factor. CONCLUSION:Histamine causes dose-dependent vasodilatation, flare and itch in the human forearm. H2 -receptors are important in this process. Our results support further exploration of combined H1 - and H2 -receptor antagonist therapy in acute allergic syndromes.
RCT Entities:
AIM: To investigate the mechanism of action of intra-arterial histamine in the human forearm vasculature. METHODS: Three studies were conducted to assess changes in forearm blood flow (FBF) using venous occlusion plethysmography in response to intra-brachial histamine. First, the dose-response was investigated by assessing FBF throughout a dose-escalating histamine infusion. Next, histamine was infused at a constant dose to assess acute tolerance. Finally, a four way, double-blind, randomized, placebo-controlled crossover study was conducted to assess FBF response to histamine in the presence of H1 - and H2 -receptor antagonists. Flare and itch were assessed in all studies. RESULTS:Histamine caused a dose-dependent increase in FBF, greatest with the highest dose (30 nmol min(-1) ) infused [mean (SEM) infused arm vs. control: 26.8 (5.3) vs. 2.6 ml min(-1) 100 ml(-1) ; P < 0.0001]. Dose-dependent flare and itch were demonstrated. Acute tolerance was not observed, with an increased FBF persisting throughout the infusion period. H2 -receptor antagonism significantly reduced FBF (mean (95% CI) difference from placebo at 30 nmol min(-1) histamine: -11.9 ml min(-1) 100 ml(-1) (-4.0, -19.8), P < 0.0001) and flare (mean (95% CI) difference from placebo: -403.7 cm(2) (-231.4, 576.0), P < 0.0001). No reduction in FBF or flare was observed in response to the H1 -receptor antagonist. Itch was unaffected by the treatments. Histamine did not stimulate vascular release of tissue plasminogen activator or von Willebrand factor. CONCLUSION:Histamine causes dose-dependent vasodilatation, flare and itch in the human forearm. H2 -receptors are important in this process. Our results support further exploration of combined H1 - and H2 -receptor antagonist therapy in acute allergic syndromes.
Authors: Sheldon L Spector; Richard A Nicklas; Jean A Chapman; I Leonard Bernstein; William E Berger; Joann Blessing-Moore; Mark S Dykewicz; Stanley M Fineman; Rufus E Lee; James T Li; Jay M Portnoy; Diane E Schuller; David Lang; Stephen A Tilles Journal: Ann Allergy Asthma Immunol Date: 2003-08 Impact factor: 6.347
Authors: B Jilma; T Pernerstorfer; E Dirnberger; P Stohlawetz; L Schmetterer; E A Singer; U Grasseli; H G Eichler; S Kapiotis Journal: J Lab Clin Med Date: 1998-02
Authors: K Rossbach; C Nassenstein; M Gschwandtner; D Schnell; K Sander; R Seifert; H Stark; M Kietzmann; W Bäumer Journal: Neuroscience Date: 2011-06-13 Impact factor: 3.590
Authors: Matthew R Ely; Stephen M Ratchford; D Taylor La Salle; Joel D Trinity; D Walter Wray; John R Halliwill Journal: J Appl Physiol (1985) Date: 2020-05-14
Authors: Daniel J Wilkinson; Giovanny Rodriguez-Blanco; Warwick B Dunn; Bethan E Phillips; John P Williams; Paul L Greenhaff; Kenneth Smith; Iain J Gallagher; Philip J Atherton Journal: Aging (Albany NY) Date: 2020-06-24 Impact factor: 5.682